JPRN-UMIN000028650
Completed
N/A
Intranasal Oxytocin for Autism Spectrum Disorder and Comorbid Severe Intellectual Disabilities:Open-label long term study - Intranasal Oxytocin for Autism Spectrum Disorder and Comorbid Severe Intellectual Disabilities:Open-label long term study
ational Hospital Organization Hizen Psychiatric Center0 sites3 target enrollmentSeptember 1, 2017
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Autism Spectrum Disorder Severe intellectual disabilities
- Sponsor
- ational Hospital Organization Hizen Psychiatric Center
- Enrollment
- 3
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •CARS\-TV less than 30 points self\-standing position impossible Weight under 20kg History of status epilepticus possibility of pregnancy Physical exhaustion and advanced inspection value or more
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Intranasal Oxytocin for Autism Spectrum Disorder and Comorbid Severe Intellectual Disabilities:open-label studyAutism spectrum disorder severe intellectual disabilitiesJPRN-UMIN000024339ational Hospital Organization Hizen Psychiatric Center7
Recruiting
Phase 2
Oxytocin in Preschoolers with Autism receiving Social Learning TherapyAutism Spectrum DisordersMental Health - Autistic spectrum disordersACTRN12618001029280niversity of Sydney132
Active, Not Recruiting
Phase 1
The use of Oxytocin for Autism Spectrum Disorders: Investigating theeffect on behavior and at the level of the brain.Young male adults with Autism Spectrum Disorders (18-30 years)MedDRA version: 16.1Level: LLTClassification code 10003808Term: Autistic disorderSystem Organ Class: 100000004852Therapeutic area: Psychiatry and Psychology [F] - Psychological processes [F02]EUCTR2014-000586-45-BEKU Leuven40
Completed
N/A
Intranasal Oxytocin for the Treatment of Autism Spectrum DisordersAutism Spectrum DisordersNCT01337687Montefiore Medical Center19
Completed
Phase 2
Single Dose Intranasal Oxytocin and Cognitive Effects in AutismAutism Spectrum DisordersNCT02493426University of Minnesota27